Genzyme's Myozyme approved

An FDA panel of health experts voted to support approval for mass production of Genzyme's Myozyme for the treatment of Pompe disease, a rare muscle disorder that can lead to fatal respiratory problems. The FDA panel members ruled, 16-1, that the drug was effective, and most recommended accelerated approval of Myozyme, so long as Genzyme was diligent with follow-up. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.